Literature DB >> 18704350

[Treatment of osteoporosis according to the "European Guidance 2008". Fracture-oriented--economical--cost-effective].

R Bartl1.   

Abstract

Osteoporosis is one of the ten most important and widespread global diseases. In Germany alone the costs of osteoporosis run into billions of Euros. However, during the past 15 years great progress has been made both in diagnosis and in the development of new medications. Osteoporosis is now taken very seriously and recognized as a national and global disorder which is now both preventable and treatable. Nevertheless, at a practical level, both in Europe and especially in Germany, osteoporosis remains an underdiagnosed and undertreated disease. In Germany, only about 10-15% of patients with manifest osteoporosis are properly treated. The consequences of such inadequate care are high additional costs-not to mention the unnecessary suffering of the patients involved. However, in support of national guidelines, a new edition of the "European Position Paper for the Diagnosis and Management of Osteoporosis" provides the doctors who treat patients with osteoporosis with additional information and therefore more confidence. In this paper several aspects are emphasized: improvements in diagnostic evaluation, assessment of the efficacy of fracture-oriented medications, and cost-effectiveness of the treatment of patients with osteoporosis.

Entities:  

Mesh:

Year:  2008        PMID: 18704350     DOI: 10.1007/s00108-008-2192-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Biochemical indices of bone turnover and the assessment of fracture probability.

Authors:  O Johnell; A Odén; C De Laet; P Garnero; P D Delmas; J A Kanis
Journal:  Osteoporos Int       Date:  2002-07       Impact factor: 4.507

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

Authors:  O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2006-09-16       Impact factor: 4.507

4.  Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.

Authors:  Pierre D Delmas; René Rizzoli; Cyrus Cooper; Jean-Yves Reginster
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.

Authors:  John A Kanis; Olof Johnell; Anders Oden; Frederik Borgstrom; Helena Johansson; Chris De Laet; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2004-04-22       Impact factor: 4.507

Review 7.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

8.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

9.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24

10.  Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.

Authors:  M Pazianas; W A Blumentals; P D Miller
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more
  1 in total

Review 1.  [Current prevention and treatment strategies for osteoporosis. Fracture-oriented, effective, low side effects and inexpensive].

Authors:  R Bartl; C Bartl
Journal:  Internist (Berl)       Date:  2015-12       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.